新制剂的 "重磅 "时刻即将结束：新型三抗药物雷曲肽治疗肥胖症评述。

IF 1.1 Q4 PHARMACOLOGY & PHARMACY

Journal of Pharmacy Technology Pub Date : 2024-12-01 Epub Date: 2024-10-19 DOI:10.1177/87551225241285326

Maryam Deravi, Chris Piszczatoski, Bradley Phillips, Jessica Huston, Angelina Vascimini

{"title":"新制剂的 \"重磅 \"时刻即将结束：新型三抗药物雷曲肽治疗肥胖症评述。","authors":"Maryam Deravi, Chris Piszczatoski, Bradley Phillips, Jessica Huston, Angelina Vascimini","doi":"10.1177/87551225241285326","DOIUrl":null,"url":null,"abstract":"Retatrutide, a hormone receptor agonist targeting glucagon, glucagon-like peptide 1, and glucose-dependent insulinotropic polypeptide, is being developed to treat obesity. A literature review from April 2019 to April 2024 included such terms as \"retatrutide,\" \"LY3437943,\" \"overweight,\" and \"obesity.\" Phase I proof-of-concept studies led to phase II trials showing up to 24% body weight reduction and nearly 20 cm waist circumference reduction. The most common adverse effects were gastrointestinal. Ongoing phase II and III studies aim to further evaluate the safety and efficacy of retatrutide as a novel triagonist for obesity treatment.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11536522/pdf/","citationCount":"0","resultStr":"{\"title\":\"The \\\"Weight\\\" for a New Agent Is Almost Over: A Commentary on the Novel Triagonist Retatrutide for Obesity.\",\"authors\":\"Maryam Deravi, Chris Piszczatoski, Bradley Phillips, Jessica Huston, Angelina Vascimini\",\"doi\":\"10.1177/87551225241285326\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Retatrutide, a hormone receptor agonist targeting glucagon, glucagon-like peptide 1, and glucose-dependent insulinotropic polypeptide, is being developed to treat obesity. A literature review from April 2019 to April 2024 included such terms as \\\"retatrutide,\\\" \\\"LY3437943,\\\" \\\"overweight,\\\" and \\\"obesity.\\\" Phase I proof-of-concept studies led to phase II trials showing up to 24% body weight reduction and nearly 20 cm waist circumference reduction. The most common adverse effects were gastrointestinal. Ongoing phase II and III studies aim to further evaluate the safety and efficacy of retatrutide as a novel triagonist for obesity treatment.\",\"PeriodicalId\":16796,\"journal\":{\"name\":\"Journal of Pharmacy Technology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11536522/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pharmacy Technology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/87551225241285326\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/19 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacy Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/87551225241285326","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/19 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

雷特鲁肽是一种激素受体激动剂，靶向胰高血糖素、胰高血糖素样肽 1 和葡萄糖依赖性促胰岛素多肽，目前正在开发用于治疗肥胖症。2019年4月至2024年4月的文献综述包括 "雷塔曲肽"、"LY3437943"、"超重 "和 "肥胖症 "等术语。I 期概念验证研究导致 II 期试验显示体重最多可减轻 24%，腰围减少近 20 厘米。最常见的不良反应是胃肠道反应。目前正在进行的 II 期和 III 期研究旨在进一步评估雷塔曲肽作为治疗肥胖症的新型三联药物的安全性和有效性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The "Weight" for a New Agent Is Almost Over: A Commentary on the Novel Triagonist Retatrutide for Obesity.

Retatrutide, a hormone receptor agonist targeting glucagon, glucagon-like peptide 1, and glucose-dependent insulinotropic polypeptide, is being developed to treat obesity. A literature review from April 2019 to April 2024 included such terms as "retatrutide," "LY3437943," "overweight," and "obesity." Phase I proof-of-concept studies led to phase II trials showing up to 24% body weight reduction and nearly 20 cm waist circumference reduction. The most common adverse effects were gastrointestinal. Ongoing phase II and III studies aim to further evaluate the safety and efficacy of retatrutide as a novel triagonist for obesity treatment.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Pharmacy Technology PHARMACOLOGY & PHARMACY-

CiteScore

1.50

自引率

0.00%

发文量

期刊介绍： For both pharmacists and technicians, jPT provides valuable information for those interested in the entire body of pharmacy practice. jPT covers new drugs, products, and equipment; therapeutic trends; organizational, legal, and educational activities; drug distribution and administration; and includes continuing education articles.